Gentian Diagnostics announces the death of its founder Dr. Erling Sundrehagen

10 Oct 2024 09:25 CEST

Moss, 10 October 2024

Gentian Diagnostics announces with deep sadness the passing of Dr. Erling
Sundrehagen, the founder and a driving force behind the development of the
company, on 9 October 2024.

Dr. Sundrehagen had a distinguished career in the medical, bioanalytical, and
in-vitro diagnostic (IVD) sciences. He earned his cand.med. degree from the
University of Oslo in 1976, and subsequently obtained a cand.real. (M.Sc.) in
nuclear chemistry and related scientific fields in 1978. In 1984, he was awarded
his Dr.med. degree from the same institution. Dr. Sundrehagen’s clinical
expertise encompassed various roles as a consultant and resident at prominent
hospitals and institutions, including the Norwegian Radium Hospital. He was a
pioneering figure in protein variant analysis, held numerous international
patents, and received several international awards for his groundbreaking
contributions.

In the mid 1980’s Dr. Sundrehagen founded Axis Biochemicals which in 1999,
merged with UK-based Shield Diagnostics, forming Axis-Shield, a significant
international player within the IVD sector. Dr. Sundrehagen held several senior
positions within these organizations before founding Gentian Diagnostics, where
he played a crucial role in the company’s development as its Chief Scientific
Officer (CSO).

In his later years, Dr. Sundrehagen served as the Consulting Founder to Gentian
Diagnostics, a role he maintained until his passing.

The Company expresses its deepest gratitude for Dr. Sundrehagen's invaluable
contributions to Gentian Diagnostics and the IVD field and extend its heartfelt
condolences to his family and colleagues.

IR and press contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525

More information:
Access the news on Oslo Bors NewsWeb site

629320_2024 10 10 PR_Erling sundrehagen passing .pdf